Q1 trading update and outlook for 2026

AI SummaryClose X

CelLBxHealth plc reported its Q1 2026 trading update, highlighting significant cost-saving measures that have reduced annual cash operating costs by over £6.6 million, with a further £0.1 million expected in Q2 2026, bringing headcount down to 39 FTEs. The company ended Q1 with £4.3 million in cash. Looking ahead, CelLBxHealth is confident in achieving FY 2026 revenues of at least £2.1 million, a 50% increase from FY 2025, and is in advanced discussions with a major US healthcare provider and a top ten global pharmaceutical company regarding its Parsortix® platform.

Disclaimer*

UK 100

Latest directors dealings